PharmaShots | Incisive News in 3 Shots

Subscribe Now

Pfizer

Pfizer’s Litfulo (ritlecitinib) Receives EC’s Approval for Adolescents and Adults with Severe Alopecia Areata

Pfizer’s Litfulo (ritlecitinib) Receives EC’s Approval for Adolescents and Adults with Severe Alopecia Areata

September 19, 2023

Pfizer’s Vydura (rimegepant) Receives NICE Recommendation for Acute Treatment of Migraine

Pfizer’s Vydura (rimegepant) Receives NICE Recommendation for Acute Treatment of Migraine

September 15, 2023

Pfizer and BioNTech Receive the EMA’s CHMP Positive Opinion Recommending Marketing Authorization for Omicron XBB.1.5-adapted COVID-19 Vaccine

Pfizer and BioNTech Receive the EMA’s CHMP Positive Opinion Recommending Marketing Authorization for Omicron XBB.1.5-adapted COVID...

August 30, 2023

Pfizer’s Abrysvo Receives EC’s Marketing Authorization to Protect Infants through Maternal Immunization and Older Adults from RSV

Pfizer’s Abrysvo Receives EC’s Marketing Authorization to Protect Infants through Maternal Immunization and Older Adults from RSV

August 25, 2023

Pfizer’s Abrysvo (bivalent RSV prefusion F vaccine) Receives the US FDA’s Approval for the Prevention of Respiratory Syncytial Virus in Infants

Pfizer’s Abrysvo (bivalent RSV prefusion F vaccine) Receives the US FDA’s Approval for the Prevention of Respiratory Syncytial Vir...

August 22, 2023

$Pfizer’s Elrexfio Receives the US FDA’s Accelerated Approval for Relapsed or Refractory Multiple Myeloma$

Pfizer’s Elrexfio Receives the US FDA’s Accelerated Approval for Relapsed or Refractory Multiple Myeloma

August 16, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us